Roundtable Discussion: Co-Developing Therapeutics, Biomarkers & Clinical Endpoints to Enable Earlier Proof of Disease Modification
11:30 am - Thursday 3rd December 2026
Practical and highly interactive breakout roundtables where attendees can crowd
source solutions and share opinions around pre-assigned topic areas.
- Integrating multi-omics, spatial biology, and digital pathology to identify predictive biomarkers, pathogenic fibroblast subpopulations and novel therapeutic targets
- Aligning therapeutic mechanism, patient selection strategy and biomarker development from early discovery through clinical translation
- Determining how biomarkers can support target identification, responder stratification, treatment monitoring and endpoint development across the antifibrotic pipeline
- Discussing how early integration of translational biomarkers can reduce clinical uncertainty, accelerate proof-of-concept and improve confidence in disease-modifying potential
Moderator Feedback & Audience Debate
Moderators will be assigned to each roundtable to facilitate discussion and collate
the findings. Following the roundtable discussions, they will present back to the entire
delegation and open wider audience debate
